Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development

Technical420 Site Search

Returned 14 result(s).

CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics as Part of its Commitment to Strategic Growth

 Cybin Inc. (NEO:CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, today announced the signing of a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc. for up to CDN$20,161,575 (approximately USD$15.75 million) in an all-stock transaction. The Transaction is subject to the satisfaction or waiver of…

Mind Medicine Inc. Launches First Of Its Kind Clinical Trials Using Synergistic Psychedelic Compounds

After Champignon Brands was issued a cease trade order from the SEC, the entire psychedelic therapy sector came under pressure and this is a trend that we have been closely following. Although we believe that investors need to conduct significant due diligence and be selective when it comes to the…

Numinus Announces Closing of Oversubscribed $4.6 Million Offering

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), is pleased to announce that it has closed its previously announced short form prospectus offering, on a best efforts basis, including the exercise of the agent's option in its entirety in the form of units of the Company (each, a "Unit"). A…

Cybin Corp. Is A Multi-Faceted Life Sciences Company Investors Should Have On Their Radar

Cybin Corp. is a life sciences company that is focused on the pharmaceutical development of psychedelic products as well as the functional mushroom market. The emerging business is laser focused on the development of products and protocols in the psychedelic, pharmaceutical and nutraceutical sectors and has an intellectual property (IP)…

Novamind Closes the Acquisition of Cedar Psychiatry, a Leading Psychedelic Therapy Organization in the U.S.

Novamind Ventures Inc., a mental health and wellness company specialized in psychedelic-assisted psychotherapy, is pleased to announce that it has closed the acquisitions of Cedar Psychiatry LLC (“Cedar Psychiatry”), a specialized provider of ketamine-assisted psychotherapy and Cedar Clinical Research LLC (“Cedar Clinical Research”), a dedicated research center focused on psychedelic…

Psychedelic Assisted Therapy Is Becoming A Very Real Alternative Method To Treat Mental Illness

Although the functional mushroom market has been getting a lot of attention, we are most excited about the progress that has been made on the biotech side of the psychedelic industry. There are a few companies in advanced stages of U.S. Food and Drug Administration (FDA) clinical trials and the…

The Psychedelic Legalization Movement Is In Full Bloom

During the last year, we have seen an increase in the number of governments that are easing regulations against the psychedelic market. Most notably, major cities in California, Colorado and Oregon, have decriminalized psilocybin and this is a development that our readers need to be aware of. The easing of…

Mydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading European Research Institute

Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce that, further to its press release of July 14, 2020, its prospective acquisition target NeuroPharm Inc. ("NeuroPharm"), a developer of natural health, psychedelic based treatments for PTSD and other serious mental health disorders in…

Will Psychedelics Take The Same Trip Down The Road To Legalization As The Cannabis Industry?

During the last year, we have seen an increase in the number of governments that are easing regulations against the psychedelic market. Most notably, major cities in California, Colorado and Oregon, have decriminalized psilocybin and this is a development that our readers need to be aware of. The easing of…

Pure Extracts Has Significant Leverage To Both The Cannabis and Psychedelic Sectors

Pure Extract Technologies Inc. (“Pure Extracts”) represents a differentiated growth opportunity that has attractive leverage to both the cannabis extraction and the psychedelics markets. We have a favorable outlook on how the business is approaching each of these markets and find this to be significant. While most companies are focused…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link